巴格列酮
巴格列酮 性质
| 密度 | 1.45±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 不溶于水； DMSO 中≥15.45 mg/mL；温和加热和超声波下，乙醇中≥2.18 mg/mL |
| 形态 | 固体 |
| 酸度系数(pKa) | 6.33±0.50(Predicted) |
巴格列酮 用途与合成方法
|
PPARγ 351 nM (EC 50 , Human PPARγ) |
Balaglitazone is a selective partial PPARγ agonist with an EC 50 of 1.351 μM. Balaglitazone (5-100 μM) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC 50 s of 0.117 μM and 0.53 μM, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 µM) increases Rh123 accumulation in K562/DOX cells, but does not increases MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition.
Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPARγ agonist rosiglitazone. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone.
巴格列酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-16086 | 巴格列酮 | 199113-98-9 | 5mg | 1900 |
| 2024-01-25 | HY-16086 | 巴格列酮 | 199113-98-9 | 10mM * 1mLin DMSO | 2090 |
